James Huang Joins KPCB in Shanghai

Kleiner Perkins Caufield & Byers has added James Huang as a partner in its Shanghai offices. Huang will advise on life science investments. Huang joins from life science-focused Vivo Ventures, where he was a managing partner. Earlier in his career, Huang was president of Anesiva, a biopharmaceutical company focused on pain management.

PRESS RELEASE
Kleiner Perkins Caufield & Byers (KPCB) today announced that James Huang, a ranking executive for several pharmaceutical industry giants over the last 20 years, has joined the firm as a partner in Shanghai, China. Huang will advise on life science investment opportunities in China.

“KPCB’s expanding presence in China provides a great vehicle for driving innovation in the region’s growing pharmaceutical markets,” said Huang. “I look forward to assisting entrepreneurs with their efforts to bring innovative new products to market.”

“With his extensive business development and operating experience, James will be a tremendous asset for innovators looking to develop successful pharmaceutical companies in China,” said Tina Ju, a managing partner and co-founder of KPCB China.

Huang joins KPCB from Vivo Ventures, a venture capital firm specializing in life science investments, where he was a managing partner. Prior to Vivo, Huang was president of Anesiva, a biopharmaceutical company focused on pain management treatments. He’s also held senior roles with Tularik, Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. He received an M.B.A. from Stanford Graduate School of Business and earned a B.S. degree in Chemical Engineering from University of California, Berkeley.

About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in over 500 ventures, including AOL, Amazon, Citrix, Compaq, Electronic Arts, Genentech, Google, Intuit, Juniper Networks, Netscape, Sun, Symantec, Verisign and Zynga. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm’s portfolio companies have gone public. Many other ventureshave achieved success through mergers and acquisitions.